Shares of Helix BioPharma Corp. (TSE:HBP – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday. The company traded as low as C$1.10 and last traded at C$1.10, with a volume of 44539 shares trading hands. The stock had previously closed at C$1.17.
Helix BioPharma Stock Performance
The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44. The firm has a market cap of C$84.02 million, a PE ratio of -27.50 and a beta of 0.72. The company’s 50-day moving average is C$1.63 and its 200 day moving average is C$1.66.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Featured Articles
- Five stocks we like better than Helix BioPharma
- Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the Test
- Cintas Raises Guidance as a Major Catalyst Moves Closer
- 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
- Dave’s Success Has Investors Split
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
